• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

What's next after fistula first: is an arteriovenous graft or central venous catheter preferable when an arteriovenous fistula is not possible?

作者信息

James Matthew T, Manns Braden J, Hemmelgarn Brenda R, Ravani Pietro

机构信息

Department of Medicine, University of Calgary, Alberta, Canada.

出版信息

Semin Dial. 2009 Sep-Oct;22(5):539-44. doi: 10.1111/j.1525-139X.2009.00633.x. Epub 2009 Sep 9.

DOI:10.1111/j.1525-139X.2009.00633.x
PMID:19744149
Abstract

Findings from observational studies have established that the arteriovenous fistula (AVF) is the preferred form of vascular access for chronic hemodialysis. Unfortunately, in a subset of patients with end-stage renal disease, an AVF cannot be placed or fails to mature. In these patients an alternate form of vascular access, either an arteriovenous graft (AVG) or central venous catheter (CVC) must be selected. In this review we discuss the findings and limitations of studies examining the effect of access type (AVG or CVC) on clinical endpoints including mortality, quality of life, occurrence of infections, as well as the impact of the different access types on resource requirements. Specifically, we examine whether findings from previous studies are valid and applicable to patients for whom an AVF is not possible, and outline the need for future randomized clinical trials addressing this question.

摘要

相似文献

1
What's next after fistula first: is an arteriovenous graft or central venous catheter preferable when an arteriovenous fistula is not possible?
Semin Dial. 2009 Sep-Oct;22(5):539-44. doi: 10.1111/j.1525-139X.2009.00633.x. Epub 2009 Sep 9.
2
Vascular Access Management II: AVF/AVG cannulation techniques and complications.
J Ren Care. 2009 Jun;35(2):90-8. doi: 10.1111/j.1755-6686.2009.00095.x.
3
Vascular access for hemodialysis: the impact on morbidity and mortality.血液透析的血管通路:对发病率和死亡率的影响。
J Nephrol. 2004 Jan-Feb;17(1):19-25.
4
Secondary arteriovenous fistulas: converting prosthetic AV grafts to autogenous dialysis access.继发性动静脉瘘:将人工血管动静脉移植物转换为自体透析通路。
Semin Dial. 2008 Sep-Oct;21(5):474-82. doi: 10.1111/j.1525-139X.2008.00459.x. Epub 2008 Jun 20.
5
Conversion of vascular access type among incident hemodialysis patients: description and association with mortality.新接受血液透析患者的血管通路类型转换:描述及其与死亡率的关联
Am J Kidney Dis. 2009 May;53(5):804-14. doi: 10.1053/j.ajkd.2008.11.031. Epub 2009 Mar 5.
6
[Vascular access for dialysis in elderly: AVF versus permanent CVC].
G Ital Nefrol. 2008 Nov-Dec;25(6):614-8.
7
[When native arteriovenous fistula is not possible: the permanent catheter is better].[当无法建立自体动静脉内瘘时:永久性导管更佳]
G Ital Nefrol. 2009 Mar-Apr;26(2):154-7.
8
Fluid mechanics and clinical success of central venous catheters for dialysis--answers to simple but persisting problems.用于透析的中心静脉导管的流体力学与临床成效——对简单但长期存在问题的解答
Semin Dial. 2007 May-Jun;20(3):237-56. doi: 10.1111/j.1525-139X.2007.00284.x.
9
Do central venous catheters have advantages over arteriovenous fistulas or grafts?中心静脉导管比动静脉内瘘或移植物有优势吗?
J Nephrol. 2006 May-Jun;19(3):265-79.
10
[Analysis of the survival of permanent vascular access ports].[永久性血管通路端口的存活情况分析]
Nefrologia. 2001 May-Jun;21(3):260-73.

引用本文的文献

1
Challenges of caring for an advanced chronic kidney disease patient with severe thrombocytopenia.照顾一名患有严重血小板减少症的晚期慢性肾病患者所面临的挑战。
Clin Med Insights Case Rep. 2013 Nov 25;6:171-5. doi: 10.4137/CCRep.S13238. eCollection 2013.
2
Optimizing renal replacement therapy in older adults: a framework for making individualized decisions.优化老年患者的肾脏替代治疗:个体化决策框架。
Kidney Int. 2012 Aug;82(3):261-9. doi: 10.1038/ki.2011.384. Epub 2011 Nov 16.
3
Serum metalloproteinases MMP-2, MMP-9, and metalloproteinase tissue inhibitors in patients are associated with arteriovenous fistula maturation.
患者血清金属蛋白酶 MMP-2、MMP-9 和金属蛋白酶组织抑制剂与动静脉瘘成熟有关。
J Vasc Surg. 2011 Aug;54(2):454-9; discussion 459-60. doi: 10.1016/j.jvs.2011.02.056. Epub 2011 May 28.